{"groups":[{"description":"Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.\n\nafatinib dimaleate: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"FG000","title":"Treatment (Afatinib)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"32"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"23"}],"type":"Main Phase II Study"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"comment":"Based on encouraging results from the main Phase II study, a molecularly selected cohort was enrolled","type":"Molecularly Selected Cohort"},{"achievements":[{"groupId":"FG000","numSubjects":"32"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}